Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large, diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the United States, Chile, and Peru has not been known. METHODS: In this ongoing, double-blind, randomized, placebo-controlled, phase 3 clinical trial, we investigated the safety, vaccine efficacy, and immunogenicity of two doses of AZD1222 as compared with placebo in preventing the onset of symptomatic and severe coronavirus disease 2019 (Covid-19) 15 days or more after the second dose in adults, including older adults, in the United States, Chile, and Peru. RESULTS: A total of 32,451 participants underwent randomization, in a 2:1 ratio, to receive AZD1222 (21,635 participants) or placebo (10,816 participants). AZD1222 was safe, with low incidences of serious and medically attended adverse events and adverse events of special interest; the incidences were similar to those observed in the placebo group. Solicited local and systemic reactions were generally mild or moderate in both groups. Overall estimated vaccine efficacy was 74.0% (95% confidence interval [CI], 65.3 to 80.5; P<0.001) and estimated vaccine efficacy was 83.5% (95% CI, 54.2 to 94.1) in participants 65 years of age or older. High vaccine efficacy was consistent across a range of demographic subgroups. In the fully vaccinated analysis subgroup, no severe or critical symptomatic Covid-19 cases were observed among the 17,662 participants in the AZD1222 group; 8 cases were noted among the 8550 participants in the placebo group (<0.1%). The estimated vaccine efficacy for preventing SARS-CoV-2 infection (nucleocapsid antibody seroconversion) was 64.3% (95% CI, 56.1 to 71.0; P<0.001). SARS-CoV-2 spike protein binding and neutralizing antibodies increased after the first dose and increased further when measured 28 days after the second dose. CONCLUSIONS: AZD1222 was safe and efficacious in preventing symptomatic and severe Covid-19 across diverse populations that included older adults. (Funded by AstraZeneca and others; ClinicalTrials.gov number, NCT04516746.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Modified Poisson Regression Approach to Prospective Studies with Binary Data
Zou, G. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh090 · Cited by 9,615
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination
Greinacher, A., Thiele, T., Warkentin, T. E., Weisser, K., Kyrle, P. A., & Eichinger, S. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104840 · Cited by 2,259
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
Schultz, N. H., Sørvoll, I. H., Michelsen, A. E., Munthe, L. A., Lund-Johansen, F., Ahlen, M. T., Wiedmann, M., Aamodt, A.-H., Skattør, T. H., Tjønnfjord, G. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104882 · Cited by 1,452
Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389
Ramasamy, M. N., Minassian, A. M., Ewer, K. J., Flaxman, A. L., Folegatti, P. M., Owens, D. R., Voysey, M., Aley, P. K., Angus, B., Babbage, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32466-1 · Cited by 1,324
Self-citationEfficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102214 · Cited by 1,257
Self-citationMadhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · doi:10.1101/2021.02.10.21251247 · Cited by 1,257
Self-citationVoysey, M., Costa Clemens, S. A., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00432-3 · Cited by 1,119
Self-citation
Research works printed but not linked: 1
- COVID-19 Vaccine Tracker. Oxford/AstraZeneca: AZD1222. 2021 (https://covid19.trackvaccines.org/vaccines/4/).
Cited by
Items 501–600 of 670
Lin, Y., Cho, S., Hsieh, Y.-L., Chuang, Y., Hsu, C.-E., Liu, Y.-C., Sung, C.-C., Huang, Y.-H., Ku, W. L., Hsieh, M., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1402194 · Cited by 1
The development of therapeutics and vaccines against COVID-19.
Zhao, T., Wang, Z., Tong, M., & Fei, Y. (2024) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2024.116643 · Cited by 1
Feng, S., Bibi, S., Aley, P. K., Cappuccini, F., Clutterbuck, E., Conlin, K., Ebrahimi, N., Eordogh, A., Faust, S. N., Felle, S., et al. (2025) · Journal of Infection · doi:10.1016/j.jinf.2025.106423 · Cited by 2
Self-citationAdelglass, J. M., Bradley, P., Cai, M. R., Chau, G., Kalkeri, R., Cloney-Clark, S., Zhu, M., Cai, Z., Eickhoff, M., Plested, J. S., et al. (2025) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2025.03.015 · Cited by 1
Scaria, P. V., Rowe, C. G., Košík, I., Hu, Z., Renn, J. P., Alani, N., Kemanli, P., Orr-Gonzalez, S., Lambert, L., Adeyemi, K., et al. (2025) · Vaccines · doi:10.3390/vaccines13060648 · Cited by 2
“Countries outside the USA utilized a mix of inactivated virus, protein subunit, and adeno-vector-based vaccines, which were also developed relatively fast, to address the emergency [4,6,9,10].”
Guest, J. D., Zhang, Y., Flores, D., Atkins, E., Ren, K., Caì, Y., Rosenthal, K., Wang, Z., Kim, K., Chen, C. H., et al. (2025) · Vaccines · doi:10.3390/vaccines13080778 · Cited by 1
“Several vaccines have been licensed, utilizing mRNA [2,3], adenovirus [4], and recombinant protein [5] technologies, with seasonal boosters to accommodate new variants.”
Chen, P., Yen, H., Lee, H.-J., Wu, M., Park, K., & Song, Y. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2553371 · Cited by 1
Lin, W.-K., Lin, S., Chang, Y.-H., Wang, F., Nguyen, P.-A., Phuc, P. T., Burton, W., Hien, N. T., Lin, C.-C., Lam, C., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-12316-0 · Cited by 1
Bayesian Analysis of NPI and Vaccination Effects on SARS-CoV-2 Transmission in South Korea 2020–2022
Yang, C., & Jeong, Y. S. (2026) · Journal of Bacteriology and Virology · doi:10.4167/jbv.2026.56.1.058 · Cited by 1
Hussain, S. R., & Sahly, H. M. E. (2026) · Expert Review of Vaccines · doi:10.1080/14760584.2026.2667742 · Cited by 1
Vaccines for the Prevention of COVID-19 in Older Adults
Olagunju, O. J., Oyebanji, O. A., Mylonakis, E. E., & Canaday, D. H. (2026) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2025.09.003 · Cited by 1
Exploring the Development of Vaccine Platforms, With a Particular Focus on the COVID ‐19 Pandemic
Sällberg, M. (2026) · Acta Paediatrica · doi:10.1111/apa.70762 · Cited by 1
Kermer, P., Abdalla, Y., Klein, G., & Lüers, C. (2022) · Vaccine X · doi:10.1016/j.jvacx.2022.100257 · Cited by 1
“For example, local reactions were more common when using the AstraZeneca vaccine than in the pivotal study [3].”
Gender inequity and COVID-19 vaccination policies for pregnant women in the Americas
Ambrogi, I. G., Brito, L., Griner, A., & Bull, S. (2023) · Wellcome Open Research · doi:10.12688/wellcomeopenres.18939.1 · Cited by 1
Cpg 684: An Effective Adjuvant for the Inactivated COVID-19 Vaccine in Mice
Liu, J., Cang, T., Jiang, C., Li, K., Liu, S. J., Wang, H., Wang, M., Chen, Y., Shao, Y., & Liu, J. (2023) · Future Virology · doi:10.2217/fvl-2022-0172 · Cited by 1
Atreja, A., Kalra, S., & Rodríguez‐Saldaña, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_47 · Cited by 1
Elzouki, A.-N. Y., Elshafei, M. N., Aziz, A., Elzouki, I., Waheed, M. A., Farooqui, K., Azad, A. M., Habas, E. M., & Danjuma, M. I.-M. (2023) · Qatar medical journal · doi:10.5339/qmj.2023.21 · Cited by 1
Chiang, M., Wang, J., Lin, W., Yen, R., Huang, J.-Y., & Lu, C. (2023) · European journal of medical research · doi:10.1186/s40001-023-01456-1 · Cited by 1
“Swelling and pain at the administration site and ipsilateral axillary lymphadenopathy have been reported as side effects of COVID-19 vaccines [21–23].”
BackgroundOu, T.-S., Sun, Y.-S., Lai, C., Chen, W., Tsai, H., Chen, M., Chou, C., Chang, F., Peng, Y., Tsai, C.-C., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111455 · Cited by 1
González-Sánchez, Ó. A., Zaldívar, D., Cuevas, E., & González-Ortiz, L. J. (2024) · Vaccines · doi:10.3390/vaccines12010081 · Cited by 1
“…precise description of the vaccine effectiveness compared with the original single value offered by the vaccine manufacturers (blue [12] and orange [11]); (b) the length of the 95% CI obtained with the current strategy is negligible compared with those obtained with some of the other equivalent…”
BackgroundMethodResultInfluentialObesity and its Relationship with Covid-19: A Review of the Main Pharmaceutical Aspects
Hodel, K. V. S., Fonsêca, A. F., Barbosa, I. A. B., Medina, C., Alves, B. K. A. M. D. F., Maciel, C. A. D. O., Nascimento, D., Oliveira-Junior, G. S., Pedreira, L. A., de Souza, M., et al. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010264503231108070917 · Cited by 2
Goryaynov, S. V., & Gurova, O. Y. (2024) · Vaccines · doi:10.3390/vaccines12020130 · Cited by 1
Song, J., Jeong, S., Choi, S., Oh, Y. H., Park, S. J., Chang, J. Y., Cho, Y., Byeon, K., Choi, J. Y., Lee, S., et al. (2024) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2024.02.005 · Cited by 3
Singh, N., Singh, J., Bhandari, V., & Kumar, R. (2024) · AMEI's Current Trends in Diagnosis & Treatment · doi:10.5005/jp-journals-10055-0166 · Cited by 1
Perception, acceptance, and adverse effects of COVID-19 vaccines: Insights from Indian population
Kumawat, R., Nimesh, A., Jalandra, R., Agrawal, S., Srinivas, H., & Ahirwar, A. K. (2024) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1668_23 · Cited by 1
COVID-19 Vaccines in the Pediatric Population: A Focus on Cardiac Patients
Lababidi, G. H., Lababidi, H., Bitar, F. F., & Arabi, M. T. (2024) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2024/2667033 · Cited by 1
“…a l s b e t w ee n d o s e s a r e a ss o c i a t e d w i t h g r e a t e r v a cc i n e e f c a c y ( iii ) E f c a c y a g a i n s t h o s p i t a l i z a t i o n r a n g e s b e t w ee n 70 % a n d 100 % d e p e n d i n g o n t h e c o n s u l t e d s t u d y [ 14 , 15 ] J a n ss e n / A d 26 .”
Geldof, J., Truyens, M., Sabino, J., Ferrante, M., Lambert, J., Lapeere, H., Hillary, T., Laethem, A. V., de Vlam, K., Verschueren, P., et al. (2024) · Vaccines · doi:10.3390/vaccines12101157 · Cited by 1
“Nonetheless, patients receiving these treatments were excluded from the original trials for SARS-CoV-2 vaccine efficacy [31–33].”
BackgroundThe Application of DNA Viruses to Biotechnology
Schieferecke, A. J., Ralph, N. K., & Schaffer, D. V. (2025) · Viruses · doi:10.3390/v17030414 · Cited by 3
“…addition, recombinant adenovirus (AdV) vaccines encoding the SARS-CoV-2 spike protein received emergency authorization during the COVID-19 pandemic in the United Kingdom (ChAdOx1 nCoV-19/AZD1222 developed by the University of Oxford partnered with the private company AstraZeneca) [25,26], US (Ad26.”
Denz, R., Meiszl, K., Ihle, P., Oberle, D., Drechsel‐Bäuerle, U., Scholz, K., Meyer, I., & Timmesfeld, N. (2025) · Communications in Statistics - Simulation and Computation · doi:10.1080/03610918.2025.2488942 · Cited by 2
“Although randomized trials have been conducted to investigate the efficacy and safety of the vaccines (Polack et al. 2020; Sadoff et al. 2021; Falsey et al. 2021; Baden et al. 2021), these trials are not sufficient to obtain a full safety profile of the vaccines before marketing, due to their…”
Testing an experimental vaccine during a public health emergency: Lessons from a Peruvian case
Lanata, C. F., Ochoa, T. J., Bancalari, E. M., Baylor, N. W., Edwards, K. M., Faden, R., Madhi, S. A., Nohynek, H., & Weijer, C. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127176 · Cited by 1
Hammadi, A. A. K. A., Alzaabi, A. A., Choker, H. B., Ibrahim, A. A., Ishaq, A., Mahboub, A. E., Dhaheri, R. S. A., Alzaabi, M. N., Collyns, T. A., ElGhazali, G. E., et al. (2025) · Vaccine X · doi:10.1016/j.jvacx.2025.100698 · Cited by 2
Criteria for judging the immune markers of COVID‐19 disease vaccines
Lin, N., Fu, H., Pu, D., Quan, Y., Li, Y., Yin, X., Wei, Y., Wang, H., Ma, X., & Wei, X. (2021) · MedComm · doi:10.1002/mco2.109
Vaccination against COVID-19 among People Living with HIV
Chaudhuri, S., Tarugu, J., Koni, K., Udayasree, K., & Hema, K. (2022) · Current Medical Issues · doi:10.4103/cmi.cmi_95_21 · Cited by 1
Seok, J. M., Na, E. J., Kim, S. G., Park, J., Park, E., Song, P., & Yang, K. I. (2022) · Journal of Sleep Medicine · doi:10.13078/jsm.210022 · Cited by 1
Insights into COVID-19 vaccines development: Translation from benchside to bedside
Houssein, M., Hossainy, A. E. A. A., soussi, J. A., Batch, J. E., El‐Samadi, L., Imam, S. E., Fakih, R., Dakdouk, H., & Khalil, M. I. M. (2022) · Health Sciences Review · doi:10.1016/j.hsr.2022.100040 · Cited by 2
Efficacy and safety of SARS-CoV-2 vaccines in living donor liver transplant recipients
Jadaun, S. S., Jakkilinki, P. D., Hasnain, A., Tarai, B., Agrawal, D., Singh, S. A., Agarwal, S. K., Gupta, S. C., & Saigal, S. (2022) · Journal of Liver Transplantation · doi:10.1016/j.liver.2022.100116 · Cited by 1
“In our study Covishield and Covaxin vaccines were used which are adenovirus vector and inactivated vaccines respectively [1,2].”
BackgroundMethodCOVID-19 Vaccine Clinical Trials: A Bird’s Eye Perspective
Chennakesavulu, P. V., Cuddapah, G. V., Keesara, M. R., Inampudi, J. V., Arremsetty, A., Moka, S., & Miryala, S. (2022) · Cureus · doi:10.7759/cureus.28066 · Cited by 2
“According to these findings, ChAdOx1 nCoV-19 may not be the best vaccine option for preventing SARS-CoV-2 transmission in the asymptomatic stage [31].”
BackgroundHernández, R. D. C. S., Zayas, E. O., Duque, R. R., Rodríguez, A. V. G., & Flores, D. M. B. (2022) · REVISTA EUGENIO ESPEJO · doi:10.37135/ee.04.15.07 · Cited by 5
Cheng, C., Hung, H., Lee, J., Huang, P.-W. D., Gu, P., Lai, Y. H., Wang, Y., Wu, T., Lee, C., Wu, T.-J., et al. (2022) · Vaccines · doi:10.3390/vaccines10111827 · Cited by 1
Rajmohan, P., Gopinathan, U. U., Saudha, N. P. A., Jose, M., Raphael, L., & Thomas, J. (2022) · Journal of Acute Disease · doi:10.4103/2221-6189.357457 · Cited by 2
COVID-19 vaccination and immune thrombocytopenia
Abe, R., & Miyakawa, Y. (2022) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.33.576 · Cited by 1
Safety and incidence of COVID-19 following ChAdOx1(AZD1222) COVID-19 vaccination in Botswana
Shava, E., Izu, A., Gaolathe, T., Walker, A., Carty, L., Georgiou, P., Kuate, L., Kgathi, C., Sekoto, T., Seonyatseng, N., et al. (2023) · Journal of Infection · doi:10.1016/j.jinf.2023.02.037 · Cited by 1
Efficacy and Safety of COVID-19 Vaccines in Different Variants and Doses: A Systematic Review
Delam, H., Moghaddam, S., & Zare, R. (2022) · Epidemiology and Health System Journal · doi:10.34172/ehsj.2022.33 · Cited by 2
Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiencyPreprint
Walz, J. S., Heitmann, J. S., Tandler, C., Marconato, M., Habibzade, T., Rittig, S. M., Tegeler, C. M., Nelde, A., Maringer, Y., Jäger, S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1693355/v1 · Cited by 1
Ryan, F., Norton, T. S., McCafferty, C., Blake, S., Stevens, N. E., James, J., Eden, G., Yee, T. C., Benson, S. C., Masavuli, M., et al. (2022) · medRxiv · doi:10.1101/2022.09.22.22280180
Sager, J. E., El‐Zailik, A., Passarell, J. A., Roepcke, S., Li, X., Aldinger, M., Nader, A., Skingsley, A., Alexander, E. L., Yeh, W. W., et al. (2022) · medRxiv · doi:10.1101/2022.11.23.22282478 · Cited by 1
Liu, Y., Sánchez‐Ovando, S., Carolan, L. A., Dowson, L., Khvorov, A., Hadiprodjo, A. J., Tseng, Y. Y., Delahunty, C., Khatami, A., Macnish, M., et al. (2023) · medRxiv · doi:10.1101/2023.06.02.23290871 · Cited by 1
Some principles for using epidemiologic study results to parameterize transmission modelsPreprint
Joshi, K., Kahn, R. J., Boyer, C., & Lipsitch, M. (2023) · medRxiv · doi:10.1101/2023.10.03.23296455 · Cited by 1
Nonreplicating Viral Vectors for Vaccine Delivery
Balar, P. C., & Chavda, V. P. (2025) · Wiley eBooks · doi:10.1002/9781394271566.ch5 · Cited by 1
Gyasi, S. F., Donkoh, E. T., Frempong, S., Asamoah, A., Raji, A. S., Baidoo, R. C., Isaac, W., Essel, D., & Asakiya, H. A. (2022) · medRxiv · doi:10.1101/2022.06.09.22276192 · Cited by 1
Naturopathic Medicine on the Frontline of the COVID-19 Pandemic
Halldorson, C. (2021) · CAND Journal · doi:10.54434/candj.94
Heterologous Vaccination for Preparing COVID-19 Pandemic
Kim, T. H. (2021) · Korean Journal of Medicine · doi:10.3904/kjm.2021.96.6.450
Mukherjee, D., Dhara, B., Basu, R., Rozario, P. V., Dudhraj, V., Mukhopadhyay, D., Roy, S., Roy, I., & Mitra, A. K. (2022) · Research Square · doi:10.21203/rs.3.pex-1835/v1
Rout, J. K., Biswas, S., Banerjee, S., Kumar, S., Das, P., & Dey, S. K. (2022) · National Journal of Laboratory Medicine · doi:10.7860/njlm/2022/52643.2582
Niesen, M. J. M., Murugadoss, K., Lenehan, P. J., Marchler‐Bauer, A., Wang, J., Connor, R. P., Brister, J. R., Venkatakrishnan, A., & Soundararajan, V. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac105
Jiao, K. (2022) · Advances in Social Science, Education and Humanities Research/Advances in social science, education and humanities research · doi:10.2991/assehr.k.220504.052 · Cited by 1
Dermatomyositis Post COVID-19 Vaccine: A Case Report
Koptian, G. G., Rodrigues, D. L. A. S., de Sousa, L. F. A., & Torigoe, D. Y. (2022) · Open Journal of Rheumatology and Autoimmune Diseases · doi:10.4236/ojra.2022.122008
“0% against COVID-19, with few serious adverse effects, the most common adverse events being auto-limited generalized pain, headache, pain at the injection site and fatigue [19].”
BackgroundAssessing the Robustness of SARS-CoV-2 Vaccine Efficacy Trials: Systematic Review and Meta-AnalysisPreprint
Hoang, T. N. A., Quach, H., Hoang, N. V., Tran, T. V., Thái, P. Q., & VOGT, F. M. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4161714
T Cell Memory to Viral Infections
Klenerman, P., & Fergusson, J. R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00135-8
Utilizing the K18-hACE2 mouse model to develop protective COVID-19 vaccines
Wong, T. Y. (2022) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.11414
NEURO-COVAX: An Italian Population-Based Study of Neurological Complications After COVID-19 VaccinesPreprint
Salsone, M., Signorelli, C., Oldani, A., Patone, M., Alberti, V. F., Castronovo, V., Mazzitelli, S., Minerva, M., & Ferini‐Strambi, L. (2022) · Research Square · doi:10.21203/rs.3.rs-1978727/v1
COVID-19: lições de uma pandemia
Silva, W. D. S., & Barreto, D. P. S. (2022) · Brazilian Journal of Health Review · doi:10.34119/bjhrv5n4-228
Audio-Vestibular Side Effects of Drugs and Vaccines in Treatment of COVID-19
Skarzynska, M. B. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106777
A spatial decision support system for optimizing expansion of COVID immunization servicesPreprint
Ouma, P., Ngom, R., Oyugi, B., Atuhebwe, P. L., Okeibunor, J., Baldé, T., & Nanyunja, M. (2022) · Research Square · doi:10.21203/rs.3.rs-1968259/v1
Fevery, J., & Dallmeier, K. (2022) · Tijdschrift voor Geneeskunde · doi:10.47671/tvg.78.22.111
Harrison, D. A., Watkinson, P., Doidge, J., Shankar‐Hari, M., Mouncey, P. R., Patone, M., Coupland, C. A. C., Hippisley‐Cox, J., & Rowan, K. (2022) · medRxiv · doi:10.1101/2022.10.03.22280649
“Randomised controlled trials of vaccine efficacy inevitably have relatively low numbers of critical care admissions,(8-10) but recent population studies suggest that vaccination reduces the risk of admission for critical care.”
BackgroundBell’s Palsy Following SARS-CoV-2 Vaccines: A Systematic Review and Meta-AnalysisPreprint
Rafati, A., Pasebani, Y., Jameie, M., Yang, Y., Jameie, M., Ilkhani, S., Amanollahi, M., Sakhaei, D., Rahimlou, M., & Kheradmand, A. (2022) · medRxiv · doi:10.1101/2022.10.26.22281537
“Quality appraisal Of the 5 RCTs, three had a low risk of bias (96-98), and two were unclear (99, 100) in the criterion "D5: detection bias" of the Cochrane assessment tool but were low risk in the rest of the criteria.”
BackgroundInfluentialA Case Report of Exfoliative Bullous Rash Following AstraZeneca Vaccine
Saleem, U., & Goh, E. S. (2022) · Cureus · doi:10.7759/cureus.31559
Hartanto, D., Nugraha, J. A., & Budhy, T. I. (2022) · Jurnal Biosains Pascasarjana · doi:10.20473/jbp.v24i2.2022.111-117
Hartanto, D., Nugraha, J. A., & Budhy, T. I. (2022) · Jurnal Biosains Pascasarjana · doi:10.20473/jbp.v24i2.2022.107-114 · Cited by 1
“Jurnal Biosains Pascasarjana Vol. 24 (2022) pp © (2022) Sekolah Pascasarjana Universitas Airlangga, Indonesia”
Les virus au service de la santé : la vaccination
Tangy, F., & Tournier, J. (2022) · médecine/sciences · doi:10.1051/medsci/2022168
Cotter, C. A., Americo, J. L., Earl, P. L., & Moss, B. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.03.518963
Reações de hipersensibilidade à vacina contra o vírus Sars-Cov-2
Cavalcanti, M. D. M., Guimarães, L. G., Barros, L. E. D. O., Magalhães, M. F., Cavalcanti, A. D. M., dos Santos, B. A., Coelho, R. L. F. D. S., & Malaman, M. F. (2022) · Brazilian Journal of Health Review · doi:10.34119/bjhrv5n6-119
Therapeutic Modalities for Coronavirus SARS-CoV-2 (COVID-19)
(2022) · Advances in Hematology and Oncology Research · doi:10.33140/ahor.05.01.06
Síndrome de Guillain-Barré asociado a la vacuna ChAdOx1-S contra covid-19
Hurtado, A. J. A., Jiménez, Á. V., Ariza, J. C. G., Martínez‐Ávila, M. C., Yánez, T. R., Rico-Fontalvo, J. E., Daza-Arnedo, R., & Macea, H. G. G. (2022) · Medicina · doi:10.56050/01205498.1669
The side effects of COVID-19 vaccines: A cross-sectional study in the eastern region of Libya
Benkhaial, A., Rabee, A. A. A., Elzahaf, R. A., Mohamed, I. E., Benkhaial, F., & Meidan, T. (2022) · Open Journal of Biomedical Research · doi:10.26629/ojbr.2022.05 · Cited by 1
Literature analysis of the efficacy of COVID-19 vaccinationsPreprint
Hulsen, T. (2022) · medRxiv · doi:10.1101/2022.12.24.22283835
“[53] presented the results of a phase 3 clinical trial on 32,451 participants (including many older adults, lacking in previous trials) on the Oxford/AstraZeneca vaccine.”
BackgroundA Study on The Efficacy of Vaccination in Elderly Patients with Breakthrough COVID-19 Infection
Choi, S., Choi, Z., Ha, C., Lee, H.-J., & Kim, C. M. (2022) · 대한임상노인의학회지 · doi:10.15656/kjcg.2022.23.2.115
Introductory Chapter: Global Research Efforts toward the Development of COVID-19 Vaccines
Abdurakhmonov, I. Y. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.108669 · Cited by 1
Signal detection of COVID ‐19 vaccines adverse events using spontaneous reports from South Korea
Jeong, H. S., & Chun, B. C. (2023) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5629 · Cited by 1
“In clinical trials of the AstraZeneca vaccine, the frequently reported local reactions were injection site pain, and systemic reactions were pain, headache, and fatigue.(29) In clinical trials of the Janssen vaccine, the frequently reported local reactions were injection site pain, and systemic reactions were headache…”
BackgroundZhou, D., Shao, H., Tu, Y., Shao, T., Zhao, M., Zhou, K., Wang, K., Tang, X., Xing, Y., Liu, Z., et al. (2023) · Health Decision · doi:10.54844/hd.2022.0295
Gründe für allergologische Diagnostik und deren Ergebnisse im Kontext von COVID-19-Vakzinierungen
Floruß, E. L., Demidova, A., Hofmann, S. C., & Balakirski, G. (2023) · Die Dermatologie · doi:10.1007/s00105-023-05152-3
“Auch in den Zulassungsstudien wurden allergische Reaktionen, Urtikaria oder Angioödeme mit ähnlicher Häufigkeit nach der Vakzinierung und im Placeboarm beobachtet [12, 13].”
BackgroundImmunogenicity of the ChAdOx1 nCoV-19 vaccine in patients with hematologic malignancies
Thookhamme, C., Navinpipat, M., Sasakul, A., Pattarakosol, P., Lertchaisataporn, K., Tawinprai, K., & Praditsuktavorn, P. (2023) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2023.12.2.107
“107 particularly severe cases of the disease [3-6]; however, the diminished efficacy of SARS-CoV-2 vaccines in patients with hematologic cancer is a concern.”
BackgroundCovid-19 vaccines and their adequacy prospects in Pakistani population; A comparative review
Awais, M. (2023) · Pure and Applied Biology · doi:10.19045/bspab.2023.120129 · Cited by 1
Weiner, D. B., Jansen, K. U., & Villafana, T. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00068-2
Self-citationProtection of COVID-19 vaccine in general and special population
Zhuang, Y. (2023) · International Conference on Modern Medicine and Global Health (ICMMGH) · doi:10.1117/12.2691859
“The results of the trial demonstrate that AZD1222 was both safe and effective in reducing symptoms and serious cv-19 in a range of demographics, including older persons [5].”
Backgroundหาญผดุงกิจ, ม., & พุทธเจริญ, โ. (2022) · Chula Digiverse · doi:10.58837/chula.the.2022.1030
อัครพรพรหม, น., เจียมจรัสรังษี, ว., & รัตนานุพงศ์, ธ. (2022) · Chula Digiverse · doi:10.58837/chula.the.2022.511
Besançon, L., Claude, S., Dauby, N., Kesteman, T., Meyerowitz‐Katz, G., & Leyrat, C. (2023) · doi:10.31219/osf.io/j8ykx
Sharma, P., Sarkar, A., Pandey, A. K., Jindal, S., Sharma, J. C., Kahlon, N., Kollabathula, P., & Jaggarwal, S. (2023) · Journal of South Asian Federation of Obstetrics and Gynaecology · doi:10.5005/jp-journals-10006-2303
Banerjee, A., Garg, R., Liu, Q., van Kessel, J., Asavajaru, A., Uhlemann, E.-M. E., Joessel, M., Hamonic, G., Khatooni, Z., Kroeker, A., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3656968/v1
Matsuyama, A., Mori, T., Ogami, A., Mafune, K., Tateishi, S., Kuwamura, M., Muramatsu, K., Fujino, Y., Mori, K., & the CORoNaWork project (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1290187
“The efficacy and side effects differ according to the type of vaccine; however, many vaccines have been shown both to prevent onset and avert severity and death (4–6).”
BackgroundAuriemma, V., Piazza, O., Scarpati, G., & Iorio, G. (2023) · Frontiers research topics · doi:10.3389/978-2-8325-4102-9
NVX-CoV2373 Efficacy in Preventing SARS-CoV-2 Infection in AdolescentsPreprint
Deming, M. E., Brown, E. R., McArthur, M. A., Schrag, S. J., Arvay, M. L., Humphrys, M. S., Ravel, J., Adelglass, J. M., Essink, B. J., Musante, D. B., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4669162
Self-citationImmunization against COVID-19: A Comprehensive Review on the Leading Vaccines
Srinivasan, A., Rajesh, V., Thamilvanan, D., Ganesh, S. K., & Chandrasekaran, S. D. (2023) · Coronaviruses · doi:10.2174/0126667975285709231219080802
Yao, M., Wang, P., Wang, M., Zheng, S.-Q., Xu, X., Zhang, Q., Yu, Q., Qin, H.-R., Meng, Y.-B., & Hong, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26869
RetractedSafety and immunogenicity of different booster vaccination schemes for COVID-19 used in El Salvador
López, X. S., Domínguez, R., Recinos, D. L., Zelaya, S., Cativo, P., & Docena, G. H. (2024) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2024.13.1.35
Plasmapheresis in post-COVID-19 myelitis: A case report
Mitarnun, W., Kongngern, L., Tantisungvarakoon, P., Boonsayomphu, T., Tianchetsada, N., & Potchanapong, T. (2024) · Qatar medical journal · doi:10.5339/qmj.2024.19
Plummer, M., & Franceschi, S. (2023) · Springer eBooks · doi:10.1007/978-1-4614-6625-3_9-1
Suplemento da Sociedade Mineira de Pediatria
(2024) · Revista Médica de Minas Gerais · doi:10.5935/2238-3182.2024v34s101
Metadata
- Authors
- Falsey, A. R., Sobieszczyk, M. E., Hirsch, I., Sproule, S., Robb, M. L., Corey, L., Neuzil, K. M., Hahn, W., Hunt, J., Mulligan, M. J., McEvoy, C., DeJesus, E., Hassman, M., Little, S. J., Pahud, B. A., Durbin, A., Pickrell, P., Daar, E. S., Bush, L., Solis, J., Carr, Q. O., Oyedele, T., Buchbinder, S., Cowden, J., Vargas, S. L., Guerreros Benavides, A., Call, R., Keefer, M. C., Kirkpatrick, B. D., Pullman, J., Tong, T., Brewinski Isaacs, M., Benkeser, D., Janes, H. E., Nason, M. C., Green, J. A., Kelly, E. J., Maaske, J., Mueller, N., Shoemaker, K., Takas, T., Marshall, R. P., Pangalos, M. N., Villafana, T., & Gonzalez-Lopez, A.
- Affiliations
- Columbia University Irving Medical Center (US)
- From the University of Rochester School of Medicine and Dentistry (A.R.F., M.C.K.) and Rochester Regional Health (A.R.F.), Rochester, and Vagelos College of Physicians and Surgeons, New York Presbyterian Columbia University Irving Medical Center, Department of Medicine, Division of Infectious Diseases (M.E.S.) and the New York University Vaccine Center (M.J.M.), New York — all in New York; Biometrics (I.H.) and Infectious Diseases (J.A.G.), Late-Stage Development, Respiratory and Immunology (R.P.M.), Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, United Kingdom; Biometrics (S.S., K.S.) and Infectious Diseases, Late-Stage Development, Respiratory and Immunology (J.M., T. Takas, T.V., A.G.-L.), Translational Medicine, Microbial Sciences, Biopharmaceuticals Research and Development (E.J.K.), and Clinical Development, Early Global Development, Oncology Research and Development (N.M.), AstraZeneca, Gaithersburg, the Walter Reed Army Institute of Research, Silver Spring (M.L.R.), t...
- Corresponding author
- Villafana, Tonya
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-12-16
- Volume
- 385
- Issue
- 25
- Pages
- 2348-2360
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8522798
- OpenAlex
- W3202234535
- Cited by
- 670
- References
- 21
- Citations by year
- 2026: 33 · 2025: 72 · 2024: 97 · 2023: 185 · 2022: 259 · 2021: 24
- FWCI
- 44.70
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- United States Government (Agreement No. W15QKN-20-9-1003)
- National Institute of Allergy and Infectious Diseases (UM1 AI 148372, UM1 AI 148450, UM1 AI 148574, UM1 AI 148684, UM1 AI 148684-03, UM1 AI 68614HVTN, UM1 AI 68618, UM1 AI 68619, UM1 AI 68635, UM1 AI 68636)
- Biomedical Advanced Research and Development Authority (W15QKN-21-9-1003)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- ChAdOx1 nCoV-19 vaccine, COVID-19 vaccines, SARS-CoV-2, vaccine efficacy, vaccine safety, immunogenicity, neutralizing antibodies, nucleocapsid antibodies, older adults, adverse events
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, Vaccine Efficacy, ChAdOx1 nCoV-19, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral, Chile, Double-Blind Method, Female, Humans, Male, Middle Aged, Peru, United States, Young Adult, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.